-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Glucagon-like peptide- 1 receptor agonist ( the GLP-1 the RA ) is a clinical practice for improving diabetic patients with cardiac vascular disease ( the CVD part) prognosis
Glucagon-like peptide- 1 receptor agonist ( the GLP-1 the RA ) is a clinical practice for improving diabetic patients with cardiac vascular diseases ( diabetic cardiac vascular CVD part) prognosis
In contrast, exenatide and risenatide improved blood glucose control, but did not have a significant effect on CVD events
At present, GLP-1 RA is recommended for diabetic patients and patients with established ASCVD or ASCVD high risk
Currently, GLP-1 RA is recommended for diabetic patients and established ASCVD or ASCVD.
Although the effect of GLP-1RA on CVD has been proved to be related to HbA1c, although the effect of GLP-1RA on CVD has been shown to be directly related to the reduction of
As recently reported in the journal Diabetes Care, Koska et al.
As recently reported in the journal Diabetes Care, Koska et al.
Patients with a heavier carotid atherosclerosis burden at baseline were included in the trial, and most of them showed calcified plaques and lipid-rich necrotic cores
The effect of exenatide once a week on the changes of cardiometabolic characteristics
The effect of exenatide once a week on the changes of cardiometabolic characteristicsThe weekly exenatide observed in this study lacks benefit on carotid plaque volume and composition, which is in line with the exenatide reduction in cardiovascular events study ( EXSCEL ) trial for CVD- caused death and non-fatal The moderate impact of the primary comprehensive endpoints, such as myocardial infarction or non-fatal stroke, was consistent with the latter following 14,752 patients for a median of 3.
The once-a-week exenatide observed in this study lacks benefit on carotid plaque volume and composition, which is in line with the exenatide reduction in cardiovascular events study ( cardiovascular events EXSCEL ) trial on deaths caused by CVD , Non-fatal myocardial infarction or non-fatal stroke and other primary comprehensive endpoints are consistent with the moderate impact, the latter of 14,752 patients were followed for a median of 3.
However, compared with placebo, the heart rate at 3 months of exenatide treatment once a week increased by 9 bpm, which was more pronounced than the heart rate increase reported in clinical trials of GLP-1 RA.
Therefore, the cardiovascular benefits of GLP-1 RA may not be entirely due to the structural changes in atherosclerotic plaques
references:
Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes.
Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes.
Diabetes Care 2021 Jun; 44(6): 1252-1253.
Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes.
https://doi.
org/10.
2337/dci20-0076
leave a message here
